Ustekinumab treatment in severe atopic dermatitis: Down-regulation of T-helper 2/22 expression.
Weiss, Doris
Ustekinumab treatment in severe atopic dermatitis: Down-regulation of T-helper 2/22 expression. [electronic resource] - Journal of the American Academy of Dermatology Jan 2017 - 91-97.e3 p. digital
Publication Type: Journal Article
1097-6787
10.1016/j.jaad.2016.07.047 doi
Adult
CD4 Lymphocyte Count
Cytokines--genetics
Dermatitis, Atopic--drug therapy
Dermatologic Agents--pharmacology
Down-Regulation--drug effects
Female
Gene Expression--drug effects
Humans
Langerhans Cells--drug effects
Male
Mast Cells--drug effects
Middle Aged
RNA, Messenger--metabolism
Severity of Illness Index
T-Lymphocytes, Cytotoxic--drug effects
Th1 Cells--metabolism
Th17 Cells--metabolism
Th2 Cells--drug effects
Ustekinumab--pharmacokinetics
Ustekinumab treatment in severe atopic dermatitis: Down-regulation of T-helper 2/22 expression. [electronic resource] - Journal of the American Academy of Dermatology Jan 2017 - 91-97.e3 p. digital
Publication Type: Journal Article
1097-6787
10.1016/j.jaad.2016.07.047 doi
Adult
CD4 Lymphocyte Count
Cytokines--genetics
Dermatitis, Atopic--drug therapy
Dermatologic Agents--pharmacology
Down-Regulation--drug effects
Female
Gene Expression--drug effects
Humans
Langerhans Cells--drug effects
Male
Mast Cells--drug effects
Middle Aged
RNA, Messenger--metabolism
Severity of Illness Index
T-Lymphocytes, Cytotoxic--drug effects
Th1 Cells--metabolism
Th17 Cells--metabolism
Th2 Cells--drug effects
Ustekinumab--pharmacokinetics